Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 March 2006, Vol. 107, No. 6, pp. 2517-2524.
Prepublished online as a Blood First Edition Paper on November 17, 2005; DOI 10.1182/blood-2005-08-3351.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2005-08-3351v1
107/6/2517    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sampath, D.
Right arrow Articles by Plunkett, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sampath, D.
Right arrow Articles by Plunkett, W.
Related Collections
Right arrow Oncogenes and Tumor Suppressors
Right arrow Signal Transduction
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial

Deepa Sampath, Jorge Cortes, Zeev Estrov, Min Du, Zheng Shi, Michael Andreeff, Varsha Gandhi, and William Plunkett

From the Departments of Experimental Therapeutics, Leukemia, and Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, TX.

Chk1 and Akt signaling facilitate survival of cells treated with nucleoside analogues. Activation of Chk1 in response to cytarabine (ara-C) induced an S-phase checkpoint characterized by the inhibition of Cdk2, cell cycle arrest, no change in constitutively active Akt, or low-stress kinase signaling in ML-1 cells. However, inhibition of Chk1 by UCN-01 in S-phase-arrested cells resulted in an abrogation of the checkpoint, inhibition of Akt, activation of JNK, and a rapid induction of apoptosis. Similarly, primary acute myelogenous leukemia (AML) blasts exposed to ara-C and UCN-01 demonstrated a selective loss in cloning potential when compared with normal progenitors. Therefore, we evaluated a pilot clinical trial of ara-C in combination with UCN-01 in patients with relapsed AML. Blasts from some patients demonstrated a previously activated Chk1-Cdk2 DNA damage response pathway that decreased during therapy. Constitutively phosphorylated Akt kinase declined on addition of UCN-01 to the ara-C infusion, an action accompanied by an activation of JNK and reduction in absolute AML blast counts. Thus, use of UCN-01 in combination with ara-C decreases Chk1 phosphorylation, inhibits the Akt survival pathway, and activates JNK during the course of therapy, offering a rationale for the cytotoxic action of this combination during AML treatment. (Blood. 2006;107:2517-2524)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Wang, X. Liu, A. Matsuda, and W. Plunkett
Repair of 2'-C-Cyano-2'-Deoxy-1-{beta}-D-arabino-Pentofuranosylcytosine-Induced DNA Single-Strand Breaks by Transcription-Coupled Nucleotide Excision Repair
Cancer Res., May 15, 2008; 68(10): 3881 - 3889.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
X. Liu, A. Matsuda, and W. Plunkett
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1- -D-arabino-pentofuranosylcytosine
Mol. Cancer Ther., January 1, 2008; 7(1): 133 - 142.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
X.-Y. Pei, Y. Dai, S. Tenorio, J. Lu, H. Harada, P. Dent, and S. Grant
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism
Blood, September 15, 2007; 110(6): 2092 - 2101.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Guo, X. Liu, K. Nishikawa, and W. Plunkett
Inhibition of topoisomerase II{alpha} and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials
Mol. Cancer Ther., May 1, 2007; 6(5): 1501 - 1508.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. J. Edelman, K. S. Bauer Jr., S. Wu, R. Smith, S. Bisacia, and J. Dancey
Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors
Clin. Cancer Res., May 1, 2007; 13(9): 2667 - 2674.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. N. Tse, R. Carvajal, and G. K. Schwartz
Targeting Checkpoint Kinase 1 in Cancer Therapeutics
Clin. Cancer Res., April 1, 2007; 13(7): 1955 - 1960.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
B. Ewald, D. Sampath, and W. Plunkett
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation
Mol. Cancer Ther., April 1, 2007; 6(4): 1239 - 1248.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
X.-Y. Pei, W. Li, Y. Dai, P. Dent, and S. Grant
Dissecting the Roles of Checkpoint Kinase 1/CDC2 and Mitogen-Activated Protein Kinase Kinase 1/2/Extracellular Signal-Regulated Kinase 1/2 in Relation to 7-Hydroxystaurosporine-Induced Apoptosis in Human Multiple Myeloma Cells
Mol. Pharmacol., December 1, 2006; 70(6): 1965 - 1973.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
Sponsor: Genentech BioOncology and and Biogen Idec
Blood Online is supported in part by
Genentech BioOncology and Biogen Idec
  Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020